Trial site
Newton-Wellesley Hospital
Newton, Massachusetts 02462, United StatesNot linked to an institution yet
- 14running trials
- 8closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 23 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Active, not recruiting13 trials
- Completed7 trials
- Recruiting1 trial
- Terminated1 trial
- Lead sponsor
- National Cancer Institute (NCI)8 trials
- Massachusetts General Hospital4 trials
- ECOG-ACRIN Cancer Research Group3 trials
- Alliance for Clinical Trials in Oncology1 trial
- ETOP IBCSG Partners Foundation1 trial
- and 5 more
Running trials
Recruiting
A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)
NCT07199738· Smith & Nephew, Inc.· Source
Contact: Hayden Box
Active, not recruiting
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
NCT03563248· Phase 2· Massachusetts General Hospital· Source
Active, not recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02718833· Phase 2· Massachusetts General Hospital· Source
Active, not recruiting
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Source
Active, not recruiting
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
NCT02115282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01208662· Phase 3· Paul Richardson, MD· Source
Active, not recruiting
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
NCT01116648· Phase 1/2· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error